Journal
ARCHIVES OF GERONTOLOGY AND GERIATRICS
Volume 96, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.archger.2021.104459
Keywords
Dementia; Functional disability; Alzheimer's disease; Medications; Polypharmacy; Lewy body dementia
Categories
Funding
- Norwegian government, through hospital owner Helse Vest (Western Norway Regional Health Authority)
- National Institute for Health Research (NIHR) Biomedical Research center at South London and Maudsley NHS Foundation Trust and King's College London
Ask authors/readers for more resources
The study found that in patients diagnosed with mild Alzheimer's disease or Lewy Body dementia, using more medications was associated with a faster functional decline, but not with cognitive decline. With disease progression, there was an increase in the number of medications prescribed, highlighting the need for careful assessment of medication use in dementia patients to potentially improve functional prognosis.
Background: In dementia, a number of factors may influence functional decline in addition to cognition. In this study, we aimed to study the potential association of the number of prescribed medications with functional decline trajectories over a five-year follow-up in people diagnosed with mild Alzheimer's disease (AD) or Lewy Body dementia (LBD). Methods: This is a longitudinal analysis of a Norwegian cohort study entitled The Dementia Study of Western Norway. We included 196 patients newly diagnosed with AD (n=111) and LBD (n=85), followed annually for 5 years. We conducted linear mixed-effects models to analyse the association of the number of medications with functional decline measured by the Rapid Disability Rating Scale - 2. Results: The mean prescribed medications at baseline was 4.18 +/- 2.60, for AD 3.92 +/- 2.51 and LBD 4.52 +/- 2.70. The number of medications increased during the follow-up; at year five the mean for AD was 7.28 +/- 4.42 and for LBD 8.11 +/- 5.16. Using more medications was associated with faster functional decline in AD (Est 0.04, SE 0.01, p-value 0.003) and LBD (Est 0.08, SE 0.03, p-value 0.008) after adjusting for age, sex, comorbidity, neuropsychiatric symptoms, and cognition. For each medication added during the follow-up, functional trajectories worsened by 1% for AD and 2% for LBD. The number of medications was not associated with cognitive decline. Conclusion: We found that higher number of medications was related to a faster functional decline, both in AD and LBD. With disease progression, there was an increase in the number of medications. Prescription in dementia should be carefully assessed, possibly improving the functional prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available